Drug intelligence / Profile preview

68Ga-NOTA-anti-MMR VHH2

Development stage: Phase 2
Lead developer: Universitair Ziekenhuis Brussel
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-NOTA-Anti-MMR VHH2 is a radiopharmaceutical PET tracer designed for the non-invasive imaging of Tumor-Associated Macrophages (TAMs) within the tumor microenvironment. It consists of the positron-emitting radioisotope Gallium-68 (68Ga) conjugated via a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) chelator to a VHH (nanobody) fragment, specifically the VHH2 clone, which targets the Macrophage Mannose Receptor (MMR, also known as CD206). MMR is highly expressed on M2-polarized macrophages, which are typically pro-tumoral and immunosuppressive. Developed by researchers at UZ Brussel and Vrije Universiteit Brussel, this tracer is primarily being investigated in patients with non-small cell lung cancer (NSCLC) and other solid tumors to assess the immune landscape and potentially predict or monitor response to immunotherapies.

Other names: Gallium-68 NOTA-anti-MMR VHH2Gallium68 NOTA-anti-MMR VHH2Gallium 68 NOTA-anti-MMR VHH268Ga-labeled anti-MMR nanobody68Ga-NOTA-anti-CD206 VHH2

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on 68Ga-NOTA-anti-MMR VHH2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NOTA-anti-MMR VHH2.

Explore the full profile